• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Medical Officer Sweiti Hussein

    10/1/25 4:54:55 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENGN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Sweiti Hussein

    (Last) (First) (Middle)
    C/O 4868 RUE LEVY, SUITE 220

    (Street)
    SAINT-LAURENT A8 H4R 2P1

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    enGene Holdings Inc. [ ENGN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/30/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $6.83 09/30/2025 A 600,000 (1) 09/30/2035 Common Shares 600,000 $0 600,000 D
    Explanation of Responses:
    1. Non-qualified stock option grant awarded as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on September 29, 2026, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to the reporting person's continued service.
    /s/ Lee Giguere, as attorney-in-fact for the Reporting Person 10/01/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ENGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENGN

    DatePrice TargetRatingAnalyst
    2/18/2025$26.00Overweight
    Piper Sandler
    2/14/2025$34.00 → $7.00Buy → Neutral
    UBS
    12/23/2024$25.00Buy
    H.C. Wainwright
    11/27/2024$23.00Outperform
    Raymond James
    11/18/2024$18.00Mkt Outperform
    JMP Securities
    8/28/2024$30.00Outperform
    Oppenheimer
    4/22/2024$30.00Overweight
    Wells Fargo
    4/15/2024$34.00Buy
    Guggenheim
    More analyst ratings

    $ENGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on enGene Holdings with a new price target

    Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00

    2/18/25 7:08:31 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Holdings downgraded by UBS with a new price target

    UBS downgraded enGene Holdings from Buy to Neutral and set a new price target of $7.00 from $34.00 previously

    2/14/25 8:16:16 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on enGene Holdings with a new price target

    H.C. Wainwright initiated coverage of enGene Holdings with a rating of Buy and set a new price target of $25.00

    12/23/24 7:22:45 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Sweiti Hussein

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    10/1/25 4:54:55 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Sweiti Hussein

    3 - enGene Holdings Inc. (0001980845) (Issuer)

    10/1/25 4:53:25 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Regulatory Officer Boyd Matthew Ross

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    7/14/25 4:10:07 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Hussein Sweiti, M.D., MSc, Chief Medical Officer, with a grant date of September 30, 2025. The inducement award for Dr. Sweiti consists of a non-qualified stock option to purchase an aggregate 600,000 of the Company's common shares. The inducement awards for the other three newly-hired employees consist of non-qualified stock options to purchase an aggregate 57,950 of the Company's common shares. The options each have an exercise price of $6.83 per share, which is equal to the clos

    10/1/25 4:03:00 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

    Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula

    9/30/25 7:30:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

    Achieved target enrollment milestone for LEGEND trial pivotal cohort in high-risk BCG unresponsive NMIBC with carcinoma in situ LEGEND's pivotal cohort data update planned for 4Q 2025 Detalimogene granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA Biologic License Application (BLA) submission planned for 2H 2026 Cash and marketable securities of $224.9 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. "Reaching target enrollment in LEGEND'

    9/11/25 4:03:00 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    SEC Filings

    View All

    enGene Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - enGene Holdings Inc. (0001980845) (Filer)

    9/30/25 7:36:10 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by enGene Holdings Inc.

    S-8 - enGene Holdings Inc. (0001980845) (Filer)

    9/11/25 4:44:20 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by enGene Holdings Inc.

    10-Q - enGene Holdings Inc. (0001980845) (Filer)

    9/11/25 4:11:26 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $4,999,993 worth of shares (561,797 units at $8.90) (SEC Form 4)

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    11/1/24 4:15:08 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $3,012,674 worth of shares (470,633 units at $6.40) (SEC Form 4)

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    10/18/24 4:15:05 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Cooper Ronald Harold Wilfred bought $57,000 worth of shares (10,000 units at $5.70) (SEC Form 4)

    4 - enGene Holdings Inc. (0001980845) (Issuer)

    10/1/24 8:02:44 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Financials

    Live finance-specific insights

    View All

    enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

    Achieved target enrollment milestone for LEGEND trial pivotal cohort in high-risk BCG unresponsive NMIBC with carcinoma in situ LEGEND's pivotal cohort data update planned for 4Q 2025 Detalimogene granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA Biologic License Application (BLA) submission planned for 2H 2026 Cash and marketable securities of $224.9 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral gene therapy company, today announced its financial results for the third quarter ended July 31, 2025, and provided a business update. "Reaching target enrollment in LEGEND'

    9/11/25 4:03:00 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

    Additional preliminary data from ongoing LEGEND study of detalimogene in pivotal cohort of BCG-unresponsive NMIBC with CIS anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track EMA Scientific Advice completed; Indicated data could be suitable for a Contingent Marketing Authorization Application Cash and marketable securities of $251.5 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. "We have seen strong

    6/12/25 8:00:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Reports First Quarter 2025 Financial Results and Provides Business Update

    Additional preliminary data from ongoing LEGEND study of detalimogene in BCG-unresponsive NMIBC with CIS, including pivotal cohort, anticipated in 2H 2025 Biologics License Application (BLA) filing planned for mid-2026 remains on track Cash and marketable securities of $272.8 million expected to provide runway into 2027 enGene Holdings Inc. (NASDAQ:ENGN, or "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. "With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our pl

    3/10/25 4:05:00 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

    SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

    11/14/24 5:48:15 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

    SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

    11/14/24 5:05:21 PM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by enGene Holdings Inc.

    SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)

    11/14/24 7:53:57 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ENGN
    Leadership Updates

    Live Leadership Updates

    View All

    enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

    Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula

    9/30/25 7:30:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Announces Board and Leadership Appointments to Support Commercial Readiness

    Philip Astley-Sparke, William Grossman and Michael Heffernan join the Board Management promotions strengthen clinical and regulatory operations Matthew Boyd named Chief Regulatory Officer, Jill Buck Chief Development Officer, and Katherine Chan Executive Director, Urology Clinical Lead enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene's strategic transit

    7/8/25 8:00:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    enGene Names Amy Pott as Chief Global Commercialization Officer

    enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co

    5/28/25 7:30:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care